@article{2839f13a596143f6a25b9878583b2ccb,
title = "Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria",
abstract = "During the past decade, a conceptual shift occurred in the field of Alzheimer's disease (AD) considering the disease as a continuum. Thanks to evolving biomarker research and substantial discoveries, it is now possible to identify the disease even at the preclinical stage before the occurrence of the first clinical symptoms. This preclinical stage of AD has become a major research focus as the field postulates that early intervention may offer the best chance of therapeutic success. To date, very little evidence is established on this {"}silent{"} stage of the disease. A clarification is needed about the definitions and lexicon, the limits, the natural history, the markers of progression, and the ethical consequence of detecting the disease at this asymptomatic stage. This article is aimed at addressing all the different issues by providing for each of them an updated review of the literature and evidence, with practical recommendations.",
keywords = "Alzheimer's disease, Amyloid PET, Asymptomatic, Biomarkers, Blood biomarkers, CSF biomarkers, Diagnostic criteria, Genetics, MRI, Pathophysiology, Preclinical, Tau PET",
author = "{Proceedings of the Meeting of the International Working Group (IWG) and the American Alzheimer's Association on {"}The Preclinical State of AD{"}; July 23, 2015; Washington DC, USA} and Bruno Dubois and Harald Hampel and Feldman, {Howard H.} and Philip Scheltens and Paul Aisen and Sandrine Andrieu and Hovagim Bakardjian and Habib Benali and Lars Bertram and Kaj Blennow and Karl Broich and Enrica Cavedo and Sebastian Crutch and Dartigues, {Jean Fran{\c c}ois} and Charles Duyckaerts and St{\'e}phane Epelbaum and Frisoni, {Giovanni B.} and Serge Gauthier and Remy Genthon and Gouw, {Alida A.} and Habert, {Marie Odile} and Holtzman, {David M.} and Miia Kivipelto and Simone Lista and Molinuevo, {Jos{\'e} Luis} and O'Bryant, {Sid E.} and Rabinovici, {Gil D.} and Christopher Rowe and Stephen Salloway and Schneider, {Lon S.} and Reisa Sperling and Marc Teichmann and Carrillo, {Maria C.} and Jeffrey Cummings and Jack, {Cliff R.}",
note = "Funding Information: H.H. is supported by the AXA Research Fund , the Fondation Universit{\'e} Pierre et Marie Curie , and the “Fondation pour la Recherche sur Alzheimer”, Paris, France. The research leading to these results has received funding from the program “Investissements d'avenir” ANR-10-IAIHU-06. S.L. is supported by the European Medical Information Framework (EMIF). R.S. is supported by the National Institute on Aging and Alzheimer's Association . Funding Information: The authors acknowledge the helpful contribution of Zaven Khachaturian as an advisor to the Working Group in charge of the article. The meeting was supported by the French International Foundation for Research in Alzheimer's disease (IFRAD). Publisher Copyright: {\textcopyright} 2016 The Alzheimer's Association.",
year = "2016",
month = mar,
day = "1",
doi = "10.1016/j.jalz.2016.02.002",
language = "English (US)",
volume = "12",
pages = "292--323",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",
number = "3",
}